Tuberculosis (TB) is a chronic, granulomatous bacterial disease with different clinical manifestations caused by Mycobacterium tuberculosis (M. tuberculosis). TB continues to be a public health problem that still maintains its importance today. Given the recent years of co-infection with HIV/AIDS and multidrug-resistant (MDR) cases, treatment for TB disease is available in combination with multiple anti-TB drugs for at least six months. Current first-line (primary) treatments for TB, administration of a combination of isoniazid (INH), rifampicin (RIF), pyrazinamide(PZA), and ethambutol(EMB) during the first two months and then based on INH and RIF treatment for a duration of more than four to seven months. In the treatment of TB, with prolonged use of anti-TB drugs, the emergence and spread of MDR and extensive drug-resistant (XDR) M. tuberculosis strains present challenges in treating TB. In this review, it was aimed to mention the general properties of first and second-line anti-TB drugs used in the treatment of TB.
Tüberküloz (TB), Mycobacterium tuberculosis (M. tuberculosis)’in sebep olduğu değişik klinik görünümlere sahip kronik, granülomatöz karakterde bakteriyel bir hastalıktır. TB günümüzde halen önemini koruyan bir halk sağlığı sorunu olmaya devam etmektedir. Son yıllarda HIV/AIDS ile ko-enfeksiyon olması ve çok ilaca dirençli (ÇİD) vakalar göz önüne alındığında TB hastalığında tedavi en az altı ay süre ile çoklu anti-TB ilaçlarla birlikte mevcut tedaviyi oluşturmaktadır. TB için mevcut birinci kuşak (primer) tedaviler, ilk iki ay boyunca izoniazid (INH), rifampisin (RIF), pirazinamid (PZA) ve etambutol (EMB) kombinasyonunun uygulanmasına ve ardından dört ila yedi aydan daha uzun süreli INH ve RIF tedavisine dayanmaktadır. TB tedavisinde, anti-TB ilaçların uzun süre kullanılması ile M. tuberculosis’in ÇİD ve yaygın ilaca dirençli (YİD) suşlarının ortaya çıkması ve yayılması TB’nin tedavisinde zorlukları beraberinde getirmektedir. Bu derlemede TB tedavisinde kullanılan birinci ve ikinci kuşak anti-TB ilaçların genel özelliklerinden bahsedilmesi amaçlanmıştır.
Primary Language | Turkish |
---|---|
Subjects | Health Care Administration |
Journal Section | Articles |
Authors | |
Early Pub Date | December 5, 2023 |
Publication Date | December 18, 2023 |
Submission Date | December 2, 2022 |
Acceptance Date | March 31, 2023 |
Published in Issue | Year 2023 Volume: 16 Issue: 3 |
MEU Journal of Health Sciences Assoc was began to the publishing process in 2008 under the supervision of Assoc. Prof. Gönül Aslan, Editor-in-Chief, and affiliated to Mersin University Institute of Health Sciences. In March 2015, Prof. Dr. Caferi Tayyar Şaşmaz undertook the Editor-in Chief position and since then he has been in charge.
Publishing in three issues per year (April - August - December), it is a multisectoral refereed scientific journal. In addition to research articles, scientific articles such as reviews, case reports and letters to the editor are published in the journal. Our journal, which has been published via e-mail since its inception, has been published both online and in print. Following the Participation Agreement signed with TÜBİTAK-ULAKBİM Dergi Park in April 2015, it has started to accept and evaluate online publications.
Mersin University Journal of Health Sciences have been indexed by Turkey Citation Index since November 16, 2011.
Mersin University Journal of Health Sciences have been indexed by ULAKBIM Medical Database from the first issue of 2016.
Mersin University Journal of Health Sciences have been indexed by DOAJ since October 02, 2019.
Article Publishing Charge Policy: Our journal has adopted an open access policy and there is no fee for article application, evaluation, and publication in our journal. All the articles published in our journal can be accessed from the Archive free of charge.
This work is licensed with Attribution-NonCommercial 4.0 International.